Durham’s BioCryst strikes deal for treatment to combat vision loss linked to diabetes
BioCryst Pharmaceuticals has struck a licensing deal with a Georgia based company for a treatment targeting vision loss among those suffering diabetic macular edema, or DME.
Read More